FrancophonIA/ELRC3.0 huggingface dataset:
English: 9 Rash includes rash erythematous, rash generalised, rash papular and rash pruritic
Slovenian: 9 Izraz izpuščaj obsega eritematozen izpuščaj, generaliziran izpuščaj, papularen izpuščaj in pruritičen izpuščaj.
English: Patients with WHO FC II and III had a mean baseline 6MWD of 353 metres.
Slovenian: in III. funkcijskem razredu po SZO so imeli izhodiščno 6-minutno prehojeno razdaljo 353 metrov.
English: → Don't breast-feed while you're taking Volibris.
Slovenian: → Med jemanjem zdravila Volibris ne smete dojiti.
English: GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com
Slovenian: Tlf: + 45 36 35 91 00 dk-info@gsk.com
English: Nasal congestion
Slovenian: Peroralna uporaba
English: The primary endpoint was the time to first occurrence of a clinical failure event, defined as: - death, or - hospitalisation for worsening PAH, - disease progression; - unsatisfactory long-term clinical response.
Slovenian: - smrt ali - sprejem v bolnišnico zaradi poslabšanja PAH, - napredovanje bolezni,
English: Therefore breast-feeding is contraindicated in patients taking ambrisentan (see section 4.3).
Slovenian: Zato je pri bolnicah, ki jemljejo ambrisentan, dojenje kontraindicirano (glejte poglavje
English: Please read the information under ‘Pregnancy'
Slovenian: • če dojite; glejte poglavje ‘Dojenje';
English: Ambrisentan
Slovenian: Astenija
English: Adverse reactions identified from 12 week placebo controlled clinical trial data are included below by system organ class and frequency.
Slovenian: V nadaljevanju so po organskih sistemih in pogostnosti navedeni neželeni učinki zdravila, ugotovljeni v 12-tedenskih s placebom nadzorovanih kliničnih preskušanjih.
English: Therefore hepatic aminotransferases (ALT and AST) should be evaluated prior to initiation of ambrisentan and treatment should not be initiated in patients with baseline values of ALT and/or AST >3xULN (see section 4.3).
Slovenian: Pri bolnikih z izhodiščnimi vrednostmi ALT ali AST ali obeh > 3x ZMN se zdravljenje z ambrisentanom ne sme uvesti (glejte poglavje 4.3).
English: GlaxoSmithKline (Ireland) Limited 12 Riverwalk
Slovenian: Malta GlaxoSmithKline (Malta) Limited
English: Uncommon3
Slovenian: Občasni3
English: Tablet core
Slovenian: Pretisni omot
English: The Cmax and AUC(0-τ) of ambrisentan increased (48% and 121%, respectively) in the presence of multiple doses of cyclosporine A. Based on these changes, the dose of ambrisentan should be limited to 5 mg once daily when co-administered with cyclosporine A (see section 4.2).
Slovenian: Med uporabo večkratnih odmerkov ciklosporina A se je Cmax ambrisentana povečala za 48 % in AUC(0- τ) ambrisentana za 121 %.
English: The effects of steady-state ambrisentan (10 mg once daily) on the pharmacokinetics of a single dose of tadalafil, and the effects of steady-state tadalafil (40 mg once daily) on the pharmacokinetics of a single dose of ambrisentan were studied in 23 healthy volunteers.
Slovenian: Pri 23 zdravih prostovoljcih so raziskali vpliv ambrisentana (10 mg enkrat na dan) v stanju dinamičnega ravnovesja na farmakokinetiko enkratnega odmerka tadalafila in vpliv tadalafila (40 mg enkrat na dan) v stanju dinamičnega ravnovesja na farmakokinetiko enkratnega odmerka ambrisentana.
English: Vial (glass) 2 ml (150 mg/ml) 1 vial + 1 syringe +
Slovenian: Velikost pakiranja viala (steklo) 2 ml (150 mg/ml) 1 viala + 1 injekcijska brizga + 2 igli
English: EU (MA) Number (Invented) name Strength Pharmaceutical Form
Slovenian: Številka (EU) dovoljenja za promet
English: The recommended dose for adults and adolescents (12 years of age and over) is 5 mg once a day.
Slovenian: Priporočeni odmerek za odrasle in mladostnike (stare 12 let in več) je 5 mg enkrat na dan.
English: It is available as tablets (5mg).
Slovenian: Na voljo je v obliki tablet (5 mg).
English: When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.
Slovenian: Če so receptorji blokirani, histamin ne more učinkovati, zaradi česar se simptomi alergije zmanjšajo.
English: The full EPAR for Desloratadine ratiopharm can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Desloratadine ratiopharm je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Desloratadine ratiopharm on 13 January 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Desloratadine ratiopharm, veljavno po vsej Evropski uniji, odobrila dne 13. januarja 2012.
English: EPAR summary for the public desloratadine
Slovenian: Povzetek EPAR za javnost desloratadin
English: This means that Desloratadine ratiopharm is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aerius.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Aerius.
English: For more information about treatment with Desloratadine ratiopharm, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Desloratadine ratiopharm preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Desloratadine ratiopharm.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Desloratadine ratiopharm.
English: Desloratadine ratiopharm is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives).
Slovenian: Zdravilo Desloratadine ratiopharm se uporablja za lajšanje simptomov alergijskega rinitisa (vnetja nosne votline, ki ga povzroči alergija, na primer seneni nahod ali alergija na pršice) ali urtikarije (bolezni kože, ki jo povzroča alergija in katere simptomi vključujejo srbenje in izpuščaje).
English: Because Desloratadine ratiopharm is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Desloratadine ratiopharm generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Desloratadine ratiopharm.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Desloratadine ratiopharm, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Therefore, the CHMP's view was that, as for Aerius, the benefit outweighs the identified risk.
Slovenian: Zato je CHMP menil, da njegove koristi, tako kot pri zdravilu Aerius, odtehtajo znana tveganja.
English: Because Desloratadine ratiopharm is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Aerius.
Slovenian: Ker je zdravilo Desloratadine ratiopharm generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Aerius.
English: Other information about Desloratadine ratiopharm
Slovenian: Druge informacije o zdravilu Desloratadine ratiopharm
English: The CHMP concluded that, in accordance with EU requirements, Desloratadine ratiopharm has been shown to have comparable quality and to be bioequivalent to Aerius.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Desloratadine ratiopharm primerljivo raven kakovosti kot zdravilo Aerius ter da mu je biološko enakovredno.
English: What are the benefits and risks of Desloratadine ratiopharm?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Desloratadine ratiopharm?
English: Desloratadine ratiopharm is a ‘generic medicine'.
Slovenian: Desloratadine ratiopharm je „generično zdravilo“.
English: The Committee recommended that Desloratadine ratiopharm be given marketing authorisation.
Slovenian: Odbor je zato priporočil, da se za zdravilo Desloratadine ratiopharm odobri dovoljenje za promet.
English: Desloratadine ratiopharm is a medicine containing the active substance desloratadine.
Slovenian: Desloratadine ratiopharm je zdravilo, ki vsebuje zdravilno učinkovino desloratadin.
English: The active substance in Desloratadine ratiopharm, desloratadine, is an antihistamine.
Slovenian: Zdravilna učinkovina zdravila Desloratadine ratiopharm je desloratadin, ki je antihistaminik.
English: Why has Desloratadine ratiopharm been approved?
Slovenian: Zakaj je bilo zdravilo Desloratadine ratiopharm odobreno?
English: How has Desloratadine ratiopharm been studied?
Slovenian: Kako je bilo zdravilo Desloratadine ratiopharm raziskano?
English: What is Desloratadine ratiopharm used for?
Slovenian: Za kaj se zdravilo Desloratadine ratiopharm uporablja?
English: It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms,
Slovenian: Desloratadin deluje kot zaviralec receptorjev, na katere se običajno veže histamin, tj. snov v telesu, ki stran 2/2
English: What is Desloratadine ratiopharm?
Slovenian: Kaj je zdravilo Desloratadine ratiopharm?
English: How is Desloratadine ratiopharm used?
Slovenian: Kako se zdravilo Desloratadine ratiopharm uporablja?
English: How does Desloratadine ratiopharm work?
Slovenian: Kako zdravilo Desloratadine ratiopharm deluje?
English: This summary was last updated in 12-2017.
Slovenian: Povzetek je bil nazadnje posodobljen 12-2017.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cubicin on 19 January 2006.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Cubicin, veljavno po vsej Evropski uniji, izdala 19. januarja 2006.
English: What measures are being taken to ensure the safe and effective use of Cubicin?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cubicin?
English: It can stop the growth of certain types of bacteria by attaching to the membrane surrounding the bacterial cell and upsetting the essential functions that keep the cell alive.
Slovenian: Ta lahko ustavi rast določenih vrst bakterij tako, da se veže na membrano, ki obdaja bakterijsko celico, in s tem prepreči bistvene funkcije, ki omogočajo preživetje celice.
English: The full EPAR for Cubicin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cubicin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Cubicin.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cubicin.
English: Effectiveness varied between the two studies because of differences in the types of patients and infections being treated.
Slovenian: Učinkovitost je bila med študijama drugačna zaradi razlik v vrstah bolnikov in zdravljenih okužb.
English: Cubicin is an antibiotic medicine, which is used to treat the following bacterial infections:
Slovenian: Cubicin je antibiotično zdravilo, ki se uporablja za zdravljenje naslednjih bakterijskih okužb:
English: The duration of treatment with Cubicin depends on the risk of complications and official recommendations.
Slovenian: Trajanje zdravljenja z zdravilom Cubicin je odvisno od tveganja za zaplete in uradnih priporočil.
English: Cubicin daptomycin
Slovenian: Cubicin daptomicin
English: ‘Complicated' means that the infection is difficult to treat, because it has spread to the deep tissues below the skin, treatment with surgery might be needed, or the patient has other conditions that might affect how well treatment works;
Slovenian: „Zapleteno“ pomeni, da je okužbo težko zdraviti, ker je razširjena v tkiva globoko pod kožo, ker je morda potreben kirurški poseg ali ker ima bolnik še druga obolenja, ki utegnejo vplivati na zdravljenje;
English: Other information about Cubicin
Slovenian: Druge informacije o zdravilu Cubicin
English: Prescribers should consider official guidance on the use of antibiotics.
Slovenian: Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi antibiotikov.
English: In the first two studies involving 1,118 adults with complicated skin and soft tissue infections (mainly wound infections and major abscesses), Cubicin was effective in 67% of patients in one study and in 85% in the other.
Slovenian: V prvih dveh študijah, ki sta vključevali 1 118 odraslih z zapletenimi oblikami okužb kože in mehkih tkiv (v glavnem okužbami ran in večjimi abscesi), je bilo zdravilo Cubicin v eni študiji učinkovito pri 67 % bolnikov, v drugi pa pri 85 %.
English: • complicated infections of the skin and soft tissue below the skin in patients from 1 year of age.
Slovenian: • zapletenih oblik okužbe kože in mehkih tkiv pod kožo pri bolnikih, starejših od enega leta.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cubicin have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cubicin upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The European Medicines Agency decided that Cubicin's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Evropska agencija za zdravila je sklenila, da so koristi zdravila Cubicin večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
English: Three main studies in adults and two in children aged between 1 and 17 years found that Cubicin was as effective as standard treatments at curing or improving infection.
Slovenian: S tremi glavnimi študijami pri odraslih in dvema pri otrocih, starih od enega do 17 let, so ugotovili, da je zdravilo Cubicin pri zdravljenju ali izboljšanju okužb enako učinkovito kot standardno zdravljenje.
English: What benefits of Cubicin have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Cubicin izkazalo v študijah?
English: The decision to treat this type of infection with Cubicin should be based on the likelihood that the medicine will work against the infection and on advice from an expert;
Slovenian: Odločitev o zdravljenju te vrste okužbe z zdravilom Cubicin mora temeljiti na verjetnosti, da bo to delovalo proti okužbi, ter nasvetu strokovnjaka;
English: What is Cubicin and what is it used for?
Slovenian: Kaj je zdravilo Cubicin in za kaj se uporablja?
English: What are the risks associated with Cubicin?
Slovenian: Kakšna tveganja so povezana z zdravilom Cubicin?
English: The first study in children and adolescents involved 396 patients with complicated skin and soft tissue infections without bacteraemia.
Slovenian: Prva študija pri otrocih in mladostnikih je vključevala 396 bolnikov z zapletenimi oblikami okužbe kože in mehkih tkiv brez bakteriemije.
English: It is used in adults when the bacteraemia is associated with either of the two infections above, or in adolescents and children from 1 year of age when the bacteraemia is associated with complicated infections of the skin and soft tissue.
Slovenian: Uporablja se pri odraslih, kadar je bakteriemija povezana s katero od zgoraj omenjenih okužb, ali pri mladostnikih in otrocih, starejših od enega leta, kadar je bakteriemija povezana z zapletenimi okužbami kože in mehkih tkiv.
English: The company that markets Cubicin will provide all doctors who are expected to use Cubicin with a dosage card to ensure the safe use of the medicine.
Slovenian: Družba, ki trži zdravilo Cubicin, bo vsem zdravnikom, ki bodo predpisovali to zdravilo, priskrbela kartico s predpisanimi odmerki, s čimer bo zagotovila varno uporabo zdravila.
English: It is not intended to provide practical advice on how to use Cubicin.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The most common side effects with Cubicin (seen in between 1 and 10 patients in 100) are infections caused by fungi (moulds and yeasts), urinary tract infections (infection of the structures that carry urine), Candida infection (a fungal infection), anaemia (low red blood cell counts), anxiety, insomnia (difficulty sleeping), dizziness, headache, hypertension (high blood pressure), hypotension (low blood pressure), gastrointestinal and abdominal pain (belly ache), nausea (feeling sick), vomiting, constipation, diarrhoea, flatulence (gas), bloating and distension (feeling as if the tummy is full), rash, pruritus (itching), pain in the limbs (arms or legs), infusion site reactions, pyrexia (fever), asthenia (weakness), abnormal liver tests and raised levels in the blood of an enzyme called CPK (a marker of muscle damage).
Slovenian: Najpogostejši neželeni učinki zdravila Cubicin (ki se pojavijo pri 1 do 10 bolnikov od 100) so glivične okužbe (okužbe, ki jih povzročajo plesni in kvasovke), okužbe sečil (okužbe struktur za odvajanje urina), okužbe s kandido (glivična okužba), anemija (nizko število rdečih krvnih celic), anksioznost, insomnija (nespečnost), omotica, glavobol, hipertenzija (visok krvni tlak), hipotenzija (nizek krvni tlak), bolečine v prebavilih in trebuhu, navzeja (siljenje na bruhanje), bruhanje, zaprtje, driska, vetrovi, napenjanje in napihnjenost (občutek polnega trebuha), izpuščaj, pruritus (srbečica), bolečine v okončinah (rokah ali nogah), reakcije na mestu infundiranja, pireksija (povišana telesna temperatura), astenija (šibkost), nenormalni rezultati jetrnih testov ter povišane ravni krvnega encima, imenovanega CPK (označevalec poškodb mišic).
English: There was insufficient evidence to support the use of Cubicin to treat bacteraemia in patients who did not have either right-sided infective endocarditis or complicated skin and softtissue infections.
Slovenian: Ni bilo dovolj dokazov v podporo uporabi zdravila Cubicin za zdravljenje bakteriemije pri bolnikih, ki niso imeli bodisi infektivnega endokarditisa desne strani bodisi zapletenih oblik okužbe kože ali mehkih tkiv.
English: Why is Cubicin approved?
Slovenian: Zakaj je bilo zdravilo Cubicin odobreno?
English: The third study involved 246 adults with bacteraemia caused by S. aureus, including 35 who also had right-sided infective endocarditis.
Slovenian: V tretjo študijo je bilo vključenih 246 odraslih z bakteriemijo, ki jo je povzročila bakterija S. aureus, vključno s 35 bolniki, ki so imeli tudi infektivni endokarditis desne strani.
English: • right-sided infective endocarditis (infection of the lining or the valves of the right side of the heart) caused by the bacterium Staphylococcus aureus (S. aureus) in adults.
Slovenian: • infektivnega endokarditisa desne strani (okužbe sluznice ali zaklopk na desni strani srca), ki ga povzroča bakterija Staphylococcus aureus (S. aureus) pri odraslih.
English: Standard treatments comprised use of antibiotics such as vancomycin, a penicillin (including oxacillin, cloxacillin, flucloxacillin and nafcillin) or a cephalosporin.
Slovenian: Standardno zdravljenje zajema uporabo antibiotikov, kot so vankomicin, penicilin (vključno z oksacilinom, kloksacilinom, flukloksacilinom in nafcilinom) ali cefalosporin.
English: The second study in children and adolescents involved 73 patients with bacteraemia caused by S. aureus.
Slovenian: Druga študija pri otrocih in mladostnikih je vključevala 73 bolnikov z bakteriemijo, ki jo je povzročila bakterija S. aureus.
English: • bacteraemia (infection of the blood) caused by S. aureus.
Slovenian: • bakteriemije (okužbe krvi), ki jo povzroča bakterija S. aureus.
English: For more information about treatment with Cubicin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Cubicin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Cubicin is given by infusion lasting 60 minutes in children aged 1 to 6 years and 30 minutes in those aged above 7 years.
Slovenian: Zdravilo Cubicin se pri otrocih, starih od enega do šest let, daje z infundiranjem, ki traja 60 minut, pri otrocih, starejših od sedem let, pa 30 minut.
English: The active substance in Cubicin, daptomycin, is an antibiotic that belongs to the group ‘lipopeptides'.
Slovenian: Zdravilna učinkovina zdravila Cubicin, daptomicin, je antibiotik, ki spada v skupino lipopeptidov.
English: For practical information about using Cubicin, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Cubicin naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Cubicin is given into a vein as an infusion lasting 30 minutes or as an injection lasting 2 minutes.
Slovenian: Zdravilo Cubicin se daje v veno z infundiranjem, ki traja 30 minut, ali z injiciranjem v trajanju dveh minut.
English: For the full list of side effects and restrictions with Cubicin, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Cubicin glejte navodilo za uporabo.
English: Serious side effects include hypersensitivity (allergic) reactions, eosinophilic pneumonia (infection of the lungs), drug rash with eosinophilia and systemic symptoms (DRESS, a severe reaction affecting the skin, blood and internal organs), angioedema (rapid swelling of deeper skin tissues) and rhabdomyolysis (breakdown of muscle fibres).
Slovenian: Resni neželeni učinki vključujejo preobčutljivostne (alergijske) reakcije, eozinofilno pljučnico (okužbo pljuč), z zdravilom povezan izpuščaj z eozinofilijo in sistemskimi simptomi (DRESS, huda reakcija, ki prizadene kožo, kri in notranje organe), angioedem (hitro otekanje globokih kožnih tkiv) in rabdomiolizo (razgradnjo mišičnih vlaken).
English: Cubicin is available as a powder that is made up into a solution for injection or infusion (drip) into a vein.
Slovenian: Zdravilo Cubicin je na voljo v obliki praška za pripravo raztopine za injiciranje ali infundiranje (kapalne infuzije) v veno.
English: In the group with endocarditis, treatment was successful in 42% (8 out of 19) of the patients receiving Cubicin compared with 44% (7 out of 16) of the patients receiving standard treatment.
Slovenian: V skupini z endokarditisom je bilo zdravljenje uspešno pri 42 % (8 od 19) bolnikov, ki so prejemali zdravilo Cubicin, in pri 44 % (7 od 16) bolnikov, ki so prejemali standardno zdravljenje.
English: Treatment was successful in 88% (227 out of 257) of the patients receiving Cubicin compared with 86% (114 out of 132) receiving standard treatment.
Slovenian: Zdravljenje je bilo uspešno pri 88 % (227 od 257) bolnikov, ki so prejemali zdravilo Cubicin, in pri 86 % (114 od 132) bolnikov, ki so prejemali standardno zdravljenje.
English: Cubicin contains the active substance daptomycin.
Slovenian: Zdravilo Cubicin vsebuje zdravilno učinkovino daptomicin.
English: Treatment was successful in 88% (45 out of 51) of the patients receiving Cubicin compared with 77% (17 out of 22) receiving standard treatment.
Slovenian: Zdravljenje je bilo uspešno pri 88 % (45 od 51) bolnikov, ki so prejemali zdravilo Cubicin, in pri 77 % (17 od 22) bolnikov, ki so prejemali standardno zdravljenje.